- Home
- JXG vs APRE Comparison
JXG vs APRE Comparison
Compare JXG & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | APRE |
|---|---|---|
| Founded | N/A | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JXG | APRE |
|---|---|---|
| Price | $4.07 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 3.0K | ★ 252.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $10.29 | $2.76 |
Technical Indicators
Market Signals| Indicator | JXG | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 51.87 |
| Support Level | $3.70 | $0.55 |
| Resistance Level | $4.34 | $1.02 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 67.24 | 56.14 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.